Please use this identifier to cite or link to this item:
Title: Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
Author: Guerreiro Castro, S
Isenberg, D
Keywords: HCC MED
Biologic Therapy
Immunosuppressive Agents
Systemic Lupus Erythematosus
Issue Date: Mar-2017
Publisher: SAGE Publications
Citation: Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85
Abstract: Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
Peer review: yes
DOI: 10.1177/1759720X17690474
Appears in Collections:MED - Artigos

Files in This Item:
File Description SizeFormat 
Ther Adv Musculos Dis.pdf1,06 MBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.